Ketek Articles
US House C'tee declines to press contempt charge
31 March 2008
US Republicans attack "too lenient" FDA
18 February 2008
EMEA restricts use of Sanofi-Aventis' Ketek
9 April 2007
US FDA restricts use of Sanofi-Aventis' Ketek
19 February 2007
FDA pulls Ketek from AECB and ABS market
22 December 2006
New Republican "hold" on FDA Commissioner
27 November 2006
Stock Commentary - Europe - week to Nov 20, 2006
27 November 2006
S-A's Ketek under investigation by FDA over liver safety
20 November 2006
Japan stock market week to Sept 4, 2006
11 September 2006
Ketek prescribing information is revised
10 July 2006
Sanofi halts Ketek trials in children
19 June 2006
Stock Commentary - Europe - week to Jan 23
30 January 2006
S-A's Ketek superior performance in CAP
6 June 2005
French drug evaluation group starts work
16 August 2004
FDA clears Aventis' Ketek
12 April 2004
Fujisawa updates status of pipeline
8 March 2004
Fujisawa reports 9-mth sales of 315B yen
23 February 2004
Aventis' Ketek launched in Japan
22 December 2003
Tokyo pharma stocks - week to Dec 15
22 December 2003
Tokyo pharma stocks - week to Dec 8
15 December 2003
Aventis disposes of Behring unit with $925M sale to Australia's CSL
15 December 2003
Aventis' Ketek cleared in Japan for CARTIs
27 October 2003
Sankyo targeting 50% share of statins market
6 October 2003
Aventis reports side effect with Ketek
21 April 2003
Aventis licenses Ketek to Sankyo, Fujisawa
17 February 2003
Aventis gets another approvable letter for Ketek from FDA
3 February 2003
Stock Commentary - Week to January 27 - Europe
3 February 2003
Aventis wins advisory panel backing for multiple Ketek claims
13 January 2003
Future competition in AECB market
17 June 2002
Aventis blockbusters driving growth
6 May 2002
Ketek as good as levofloxacin in CARTI
6 May 2002
Aventis' Ketek launched in Brazil
22 April 2002
Aventis' Ketek launched Italy, Spain
11 February 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
Aventis growth driven by strong US pharmaceutical sales
6 November 2001
First launch of Aventis' Ketek in Germany
16 October 2001
Stock Commentary - Europe
9 August 2001
Ketek registered in first market
31 July 2001
New Ketek data support efficacy in CAP
5 July 2001
Aventis' Ketek gets FDA approvable letter
6 June 2001
CPMP recommends Ketek
24 April 2001
Ketek effective in respiratory infections
9 April 2001
Aventis reveals first Phase III Ketek data at ICAAC, sees $1 billion in
28 September 2000
Aventis reveals first Phase III Ketek data at ICAAC
20 September 2000
Aventis files for European approval of Ketek
5 April 2000
Showing 1-67 of 67 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
